NeuroPace vs Owlet
Owlet reported revenue of $106 million in fiscal 2025, about the same as NeuroPace's $100 million in fiscal 2025. NeuroPace's revenue grew 25.1% in its latest year, and Owlet's grew 35.4%. NeuroPace had an operating margin of -16.3%, against -7.8% at Owlet. Free cash flow was −$11 million at NeuroPace and −$11 million at Owlet.
Side by side
| NeuroPace | Owlet | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $100M | $106M |
| Revenue growth | 25.1% | 35.4% |
| Revenue growth a year, last 5 years | 19.5% | 7.0% |
| Gross margin | 77.2% | 50.6% |
| Operating margin | −16.3% | −7.8% |
| Net margin | −21.5% | −37.5% |
| Free cash flow | −$11M | −$11M |
| Free cash flow margin | −11.3% | −10.5% |
| Return on capital | −81.8% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $50M | $0M |
| Change in diluted share count | 12.3% | 65.2% |
| Last close | $8.14 | $3.23 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $302,102, sold $399,250 | sold $295,978 |
| Piotroski F-score | 5 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
NeuroPaceOwlet
Operating margin
Percent of revenue
NeuroPaceOwlet
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NeuroPaceOwlet